NCT04785638View on ClinicalTrials.gov

An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions
Pain, PostoperativeHernia, VentralAbdominoplastyHysterectomyColectomyReduction Mammoplasty
Interventions
COMBINATION_PRODUCT

INL-001 (bupivacaine hydrochloride) implant

INL-001 (bupivacaine hydrochloride) implant

Trial Locations (8)

35630

North Alabama Medical Center, Florence

35660

Helen Keller Hospital, Sheffield

45417

Midwest Clinical Research, Dayton

77004

Daneshvari Solanki, Houston

77030

Baylor College of Medicine, Houston

77089

Memorial Hermann, Houston

78229

Endeavor Clinical Trials, San Antonio

91105

Lotus Clinical Research, Pasadena

Sponsors

Lead Sponsor

Innocoll
All Listed Sponsors
lead

Innocoll

INDUSTRY